Alzheimer’s Therapeutics Market Research Report 2022 Featuring Cipla, Torrent Pharma, Unichem, Lannett, Janssen Pharma, Novartis, Zydus Lifesciences, Sun Pharmaceutical, Dr. Reddy’s, and Aurobindo

Alzheimer's Therapeutic Market

Dublin, December 13, 2022 (GLOBE NEWSWIRE) -- The "Alzheimer's Therapeutics Market Share, Size, Trends By Drug Class, By Distribution Channel, By Region, Segment Forecast, 2022 - 2030" report has been added to researchandmarkets.com offering.

The size of the global Alzheimer's therapeutics market is expected to reach USD 14.2 billion by 2030

Global players include Cipla Ltd., Torrent Pharmaceuticals, Unichem Laboratories, Lannett Inc., Janssen Pharmaceuticals, Novartis, Zydus Lifesciences, Sun Pharmaceutical, Dr. Reddy's Laboratories, and Aurobindo.

Alzheimer's disease is a degenerative neurological condition in which memory loss and cognitive decline are caused by the death of brain cells. As the brain shrinks, intellectual, social, and behavioral skills gradually deteriorate. It is the most common cause of dementia.

Alzheimer's accounts for 60-70% of all dementia cases, making it the most frequent type. Government and non-governmental organizations are investing heavily in the development of diagnostics and therapies for the disease as a result of the increasing prevalence of the disease around the world, which could help the growth of the industry. According to the World Health Organization, the economic cost burden is enormous, ranging from $1.3 trillion to $2.8 trillion by 2030.

The patient's family, society and economy are seriously affected by AD. Both the disease and its mechanism are complex. Given the increasing incidence of AD worldwide, some research has shown the need to create an effective therapy. Memantine and acetylcholinesterase inhibitors are the only drugs used to treat this condition, even though it has been studied for more than a century.

The industry for the therapy of this disease would expand as investments in R&D by biopharmaceutical companies increase. In addition, the development of new therapies to treat, delay and prevent diseases, as well as early diagnosis of Alzheimer's disease, will create prospects for the global market for disease treatments.

The industry is expanding as a result of growing awareness of Alzheimer's disease health care and new diagnostic technologies. Due to the increasing frequency of the disease, there has recently been an increase in the use of medications for the disease. The demand for such drugs for diseases is expanding as a result of an aging population, rising health care costs, and increased government spending.

Alzheimer's Therapeutics Market Report Highlights

• The cholinesterase inhibitors segment is expected to grow at a lucrative CAGR during the forecast period as it is frequently recommended to treat symptoms related to memory, thinking, language, judgment and other applications.

• The retail pharmacy segment is expected to maintain a significant share of revenue during the forecast period due to the easy access and availability of drugs and therapies for the treatment of Alzheimer's disease.

• North America is expected to grow at a significant CAGR over the forecast period due to rapidly increasing aging populations, significant investment in research and development activities, and new product introductions.

Market segments

Alzheimers Therapeutics, Drug Class Outlook (Revenue: Billions of Dollars, 2018 - 2030)

Alzheimers Therapeutics, Distribution Channel Perspective (Revenue: Billions of Dollars, 2018 - 2030)

• Retail Pharmacies

• Hospital Pharmacies

• online pharmacies

Market dynamics

Drivers and Opportunities

Constraints and challenges

Porter's Five Forces Analysis

PESTLE Analysis

Alzheimer's Therapeutics Industry Trends

Analysis of the value chain

COVID-19 Impact Analysis

company profiles

• Teva Pharmaceuticals Ltd.

• Eisai company. Limited.

• AbbVie Inc.

• Amneal Pharmaceuticals Inc.

• Macleods Pharmaceuticals Ltd.

• Viatris Inc.

• lupine ltd.

• Cipla Ltd.

• Torrent pharmaceuticals ltd.

• Unichem Laboratories Ltd.

• lannett inc

• Janssen Pharmaceuticals Inc. (Johnson & Johnson)

• Novartis AG

• Zydus Lifesciences Ltd (CADILA)

• Sun Pharmaceutical Industries Ltd.

• Laboratories of Dr. Reddy Ltd.

• Aurobindo.

For more information on this report, visit https://www.researchandmarkets.com/r/4jdu96

Attached file

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900